Reference - Detail
| RRC ID | 18590 |
|---|---|
| Author | Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. |
| Title | Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. |
| Journal | Br J Cancer |
| Abstract |
BACKGROUND:Cholangiocarcinoma (CC) is a highly malignant carcinoma. We attempted to clarify the prognostic significance of c-Met overexpression and its association with clinicopathological factors in patients with CC. PATIENTS AND METHODS:One hundred and eleven patients with intrahepatic CC (IHCC) and 136 patients with extrahepatic CC (EHCC) who had undergone curative surgery were divided immunohistologically into c-Met(high) and c-Met(low) groups. Clinicopathological factors and outcomes were compared between the groups. c-Met and epidermal growth factor receptor (EGFR) expression was also examined in 10 CC cell lines. RESULTS:The positivity of c-Met was 45.0% in IHCC and 68.4% in EHCC; c-Met(high) expression was demonstrated in 11.7% of IHCC and 16.2% of EHCC. c-Met(high) expression was significantly correlated with the 5-year survival rate for CC overall (P=0.0046) and for IHCC (P=0.0013), histopathological classification in EHCC, and for EGFR overexpression in both IHCC and EHCC. Coexpression and coactivation of c-Met and EGFR were also observed in CC cell lines. Multivariate analysis revealed that c-Met(high) expression was an independent predictor of poor overall and disease-free survival in patients with IHCC. CONCLUSIONS:c-Met overexpression is associated with EGFR expression and is a poor prognostic factor in CC. |
| Volume | 105(1) |
| Pages | 131-8 |
| Published | 2011-6-28 |
| DOI | 10.1038/bjc.2011.199 |
| PII | bjc2011199 |
| PMID | 21673683 |
| PMC | PMC3137414 |
| MeSH | Adult Aged Aged, 80 and over Bile Duct Neoplasms / metabolism* Bile Duct Neoplasms / pathology Bile Ducts, Extrahepatic / metabolism* Bile Ducts, Extrahepatic / pathology Bile Ducts, Intrahepatic / metabolism* Bile Ducts, Intrahepatic / pathology Blotting, Western Cholangiocarcinoma / metabolism* Cholangiocarcinoma / pathology ErbB Receptors / metabolism* Female Humans Immunoenzyme Techniques Lymphatic Metastasis Male Middle Aged Prognosis Proto-Oncogene Proteins c-met / metabolism* Survival Rate |
| IF | 5.791 |
| Times Cited | 76 |
| WOS Category | ONCOLOGY |
| Resource | |
| Human and Animal Cells | TGBC24TKB(RCB1196) MKN45(RCB1001) |